tirzepatide and retatrutide vs (2026) Retatrutide vs Tirzepatide vs Semaglutide

A 'second wave' of GLP-1 development The insurer's 2026 pipeline report, which reviewed more than 440 new drug and supplemental submissions made to Health Canada in 2025, describes what it calls a second wave of GLP-1 innovation

*Outcomes based on internal analyses of self-reported member data that has not been independently verified.

Key Takeaways Wegovy and Ozempic are the brand names of the GLP-1 agonist medication semaglutide

Research shows that somewhere between 25% and 40% of the weight lost on these medications comes from lean muscle mass

References 1 AbdalkaderM.LampinenR.KanninenK

Add Chromogen solution A and B